Evidence map›Paper›PMID 35135868›Full record

ArticleJournal of neurology, neurosurgery, and psychiatry2022

CAIDE dementia risk score relates to severity and progression of cerebral small vessel disease in healthy midlife adults: the PREVENT-Dementia study.

Audrey Low, Maria A Prats-Sedano, James D Stefaniak, Elizabeth Frances McKiernan, Stephen F Carter, Maria-Eleni Douvani, Elijah Mak, Li Su, Olivia Stupart, Graciela Muniz and 4 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Journal of neurology, neurosurgery, and psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07651787 (Neurovascular and Mitochondrial Mechanisms of Transcranial Photobiomodulation in Vascular Mild Cognitive Impairment), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07651787 narecruitingnot on this mapstarted 2025, after this paper: background citation

Neurovascular and Mitochondrial Mechanisms of Transcranial Photobiomodulation in Vascular Mild Cognitive Impairment

TypeinterventionalSponsorUniversity of OklahomaRan2025 to 2026Enrolled40ConditionsMild Cognitive Impairment (MCI), Amyloid PathologyArmsActive Vielight Neuro RX-Duo device -Active transcranial photobiomodulation, Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 55 citations in OpenAlex.

  1. Brain patterns and risk factors in the FINGER RCT multimodal lifestyle intervention.The journal of prevention of Alzheimer's disease · 2025
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. A point-based cognitive impairment scoring system for southeast Asian adults.The journal of prevention of Alzheimer's disease · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Entorhinal-based path integration selectively predicts midlife risk of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Audrey LowDepartment of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK al927@medschl.cam.ac.uk.ORCID 0000-0002-2520-454X
Maria A Prats-SedanoDepartment of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
James D StefaniakDivision of Neuroscience and Experimental Psychology, The University of Manchester, Manchester, UK.
Elizabeth Frances McKiernanDepartment of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.ORCID 0000-0001-7076-8216
Stephen F CarterDepartment of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Maria-Eleni DouvaniDepartment of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Elijah MakDepartment of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Li SuDepartment of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Olivia StupartDepartment of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Graciela MunizCentre for Dementia Prevention, University of Edinburgh, Edinburgh, UK.
Karen RitchieCentre for Dementia Prevention, University of Edinburgh, Edinburgh, UK.
Craig W RitchieCentre for Dementia Prevention, University of Edinburgh, Edinburgh, UK.
Hugh S MarkusDepartment of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, Cambridge, UK.ORCID 0000-0002-9794-5996
John Tiernan O'BrienDepartment of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
University of Cambridge · GBUniversity of Edinburgh · GBInserm · FR

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundMarkers of cerebrovascular disease are common in dementia, and may be present before dementia onset. However, their clinical relevance in midlife adults at risk of future dementia remains unclear. We investigated whether the Cardiovascular Risk Factors, Ageing and Dementia (CAIDE) risk score was associated with markers of cerebral small vessel disease (SVD), and if it predicted future progression of SVD. We also determined its relationship to systemic inflammation, which has been additionally implicated in dementia and SVD.

methodsCognitively healthy midlife participants were assessed at baseline (n=185) and 2-year follow-up (n=158). To assess SVD, we quantified white matter hyperintensities (WMH), enlarged perivascular spaces (EPVS), microbleeds and lacunes. We derived composite scores of SVD burden, and subtypes of hypertensive arteriopathy and cerebral amyloid angiopathy. Inflammation was quantified using serum C-reactive protein (CRP) and fibrinogen.

resultsAt baseline, higher CAIDE scores were associated with all markers of SVD and inflammation. Longitudinally, CAIDE scores predicted greater total (p<0.001), periventricular (p<0.001) and deep (p=0.012) WMH progression, and increased CRP (p=0.017). Assessment of individual CAIDE components suggested that markers were driven by different risk factors (WMH/EPVS: age/hypertension, lacunes/deep microbleeds: hypertension/obesity). Interaction analyses demonstrated that higher CAIDE scores amplified the effect of age on SVD, and the effect of WMH on poorer memory.

conclusionHigher CAIDE scores, indicating greater risk of dementia, predicts future progression of both WMH and systemic inflammation. Findings highlight the CAIDE score's potential as both a prognostic and predictive marker in the context of cerebrovascular disease, identifying at-risk individuals who might benefit most from managing modifiable risk.

Indexed as

Cerebral Small Vessel DiseasesDementiaHypertensionAdultBiomarkersCerebral HemorrhageHumansInflammationMagnetic Resonance ImagingRisk FactorsBiomarkerscerebrovascular diseasedementia

Identifiers

PMID35135868
PMCPMC9016254
OpenAlexW4210869407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.